Luisa Iruela-Arispe named co-leader of the TEAM Program at Lurie Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Luisa Iruela-Arispe, a vascular biologist, was named co-leader of the Tumor Environment and Metastasis Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. 

The goal of the TEAM Program is to elucidate how interactions between tumor cells, immune cells, and components of the host stromal microenvironment impact tumor development and progression.

Iruela-Arispe is chair of the Department of Cell and Developmental Biology and the Stephen Walter Ranson Professor. Her research focuses on the signaling pathways that regulate vascular morphogenesis during development and pathological settings. Her cancer research interests include the molecular mechanisms that result in the emergence of angiosarcomas and the cross-talk between endothelial and tumor cells in the process of metastasis.

In collaboration with TEAM co-leader, Hidayatullah Munshi, she will help advance efforts to translate basic science discoveries from the TEAM Program into clinical practice.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login